Cahn, Avivit

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 6,382

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 2,845

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 781

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 684

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus

Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 557

The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58

Mosenzon, O., Wiviott, S. D., Heerspink, H. J. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., Rozenberg, A., Schechter, M., Yanuv, I., Murphy, S. A., et al. (2021) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 113

Digital health technology and diabetes management: 数字化医疗技术与糖尿病管理

Cahn, A., Akirov, A., & Raz, I. (2018) · Journal of Diabetes

Mobile Health and mHealth ApplicationsDiabetes Management and Education

Cited by 102

Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial

Leiter, L. A., Teoh, H., Braunwald, E., Mosenzon, O., Cahn, A., Kumar, K. M. P., Smahelova, A., Hirshberg, B., Stahre, C., Frederich, R., et al. (2015) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 87

Global status of diabetes prevention and prospects for action: A consensus statement

Ibrahim, M., Tuomilehto, J., Aschner, P., Beseler, L., Cahn, A., Eckel, R. H., Fischl, A. H., Guthrie, G., Hill, J. O., Kumwenda, M., et al. (2018) · Diabetes/Metabolism Research and Reviews

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 52

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. H. J. L., Cahn, A., Goodrich, E. L., Im, K., Bhatt, D. L., Leiter, L. A., et al. (2021) · JAMA Cardiology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 52

The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial

McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A. M., Bhatt, D. L., Leiter, L. A., Johansson, P. A., Mosenzon, O., Cahn, A., et al. (2021) · Diabetes, Obesity and Metabolism

Health Systems, Economic Evaluations, Quality of LifeDiabetes Treatment and Management

Cited by 34

Hypoglycaemia and its management in primary care setting

Ibrahim, M., Baker, J., Cahn, A., Eckel, R. H., El Sayed, N. A., Fischl, A. H., Gaede, P., Leslie, R. D., Pieralice, S., Tuccinardi, D., et al. (2020) · Diabetes/Metabolism Research and Reviews

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 21

244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial

RAZ, I., WIVIOTT, S. D., YANUV, I., ROZENBERG, A., ZELNIKER, T. A., CAHN, A., HEERSPINK, H. L., DWYER, J. P., GOODRICH, E., BHATT, D. L., et al. (2019) · Diabetes

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 15

Machine learning based study of longitudinal HbA1c trends and their association with all-cause mortality: analyses from a national diabetes registry

Cahn, A., Zuker, I., Eilenberg, R., Uziel, M., Tsadok, M. A., Raz, I., & Lutski, M. (2022) · Diabetes/Metabolism Research and Reviews

Diabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 9